European evidence based consensus on the diagnosis and management of Crohn’s disease: current management

  title={European evidence based consensus on the diagnosis and management of Crohn’s disease: current management},
  author={Simon P. L. Travis and Eduard F Stange and Marc L{\'e}mann and Tom {\"O}resland and Yehuda Chowers and Alastair Forbes and Geert R D'Haens and George Kitis and Antoine Cortot and Cosimo Prantera and Philippe Marteau and J F Colombel and Paolo Gionchetti and Yoram Bouhnik and Emmanuel Tiret and J.M.P. Kroesen and Michael J. Starlinger and Neil J. McC. Mortensen},
  pages={i16 - i35}
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn’s disease. The third section on special situations in Crohn’s disease includes postoperative recurrence… 

Overview of Medical Management of Crohn’s Disease

Crohn’s disease is a chronic relapsing inflammatory disease with both intestinal and extraintestinal manifestations that mainly affects young people, with peak incidence in the early twenties. As the

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated.

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

These guidelines were intended primarily to be used by practitioners in Japan, and the goal is to improve the outcomes of patients with Crohn’s disease.

Guidelines for the management of inflammatory bowel disease in adults

The present document is intended primarily for the use of clinicians in the United Kingdom, and serves to replace the previous BSG guidelines in IBD, while complementing recent consensus statements published by the European Crohn's and Colitis Organisation (ECCO).

The multidisciplinary health care team in the management of stenosis in Crohn’s disease

Patients with stricturing CD require complex clinical management, which benefits from a multidisciplinary approach: gastroenterologists, pediatricians, radiologists, surgeons, specialist nurses, and dieticians are among the health care providers involved in supporting these patients throughout diagnosis, prevention of complications, and treatment.

The role of budesonide in the management of Crohn's disease

An overview of Crohn's disease and the current strategies used in its pharmacological management is provided, placing specific focus on the role of budesonide in the treatment pathway.

Second Korean guidelines for the management of Crohn's disease

These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment ofCD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence.

Epidemiological description and treatment of Crohn’s disease patients

The objective of this study is to determine the disease’s prevalence, its frequent clinical manifestations, the various treatments used and the clinical response to such treatments.



Corticosteroids for maintenance of remission in Crohn's disease.

The use of conventional systemic corticosteroids in patients with clinically quiescent Crohn's disease does not appear to reduce the risk of relapse over a 24 month period of follow-up.

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.

Mesalazine as a maintenance treatment in Crohn’s disease

As is too often the case in such reviews, the authors have failed to identify all of the relevant literature pertinent to the topic: the maintenance of remission or prevention of recurrence of Crohn’s disease.

Crohn's disease: step up or top down therapy.

  • S. Hanauer
  • Medicine
    Best practice & research. Clinical gastroenterology
  • 2003
Evidence for therapeutic efficacy in Crohn's disease is presented as a prologue to considerations necessary to determine the benefits and risks of early aggressive treatment versus sequential approaches based upon disease severity.

Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.

The addition of low-dose cyclosporine to conventional treatment for Crohn's disease did not improve symptoms or reduce requirements for other forms of therapy, and analyses of the meanCrohn's Disease Activity Index and quality-of-life scores and of the use of prednisone and 5-aminosalicylates also failed to demonstrate benefit.

Predictors of severe Crohn's disease

Clinical, demographic and biological factors associated with the development of disabling disease within 5 years after the diagnosis of CD and with the time to development of severe disease were successively studied by univariate and multivariate analyses.

A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis

Most pediatric patients with inflammatory bowel disease initially responded to corticosteroids, but after 1 year, 58% of pediatric Patients with Crohn's disease and 43% of Pediatrics with ulcerative colitis either were steroid dependent or required surgery.

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

The results make possible the design of clinical trials in quiescent Crohn's disease patients with a high risk of relapse, as well as developing a prognostic index to identify those patients.

Traditional corticosteroids for induction of remission in Crohn's disease.

Although corticosteroids cause more adverse events than either placebo or low-dose 5-ASA, these adverse events did not lead to increased study withdrawal in the included studies, and Corticosteroid are effective for induction of remission in patients with CD, particularly when used for more than 15 weeks.